Viyash Scientific Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 16 Aug 2026

Company page: Viyash Scientific share price, financials & guidance record

Viyash Scientific Limited delivered a strong Q1 FY27 with robust revenue and EBITDA growth, driven by Animal Health and US Human Formulations. The company achieved a virtually debt-free status and is strategically investing in organic R&D and manufacturing, alongside the BioForLife acquisition in Italy. While API revenue was flat this quarter due to timing issues, management anticipates a rebound.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 7.9%, net profit up 23.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	42	338	42	328	340 +710%	342 +1%	372 +786%	354 +8%
Expenses	44	280	45	279	288	271	310	307
EBITDA	-2	58	-3	49	52 +2700%	70 +21%	63 +2200%	47 −4%
Margin	-5%	17%	-7%	15%	15%	21%	17%	13%
Other income	12	13	12	12	16	-25	20	15
Interest	1	6	1	6	4	4	3	1
Depreciation	2	32	2	31	31	31	31	32
Profit before tax	6	34	6	24	33 +450%	11 −68%	49 +717%	28 +17%
Tax rate	34%	-52%	28%	28%	30%	101%	27%	25%
Net profit	4	51	4	17	23 +475%	0 −100%	36 +800%	21 +24%
EPS	0.17	2.04	0.17	0.69	0.91	0.00	0.82	0.48

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls